25 April 2017
Dmitry Kurochkin, Vice-President of the Chamber of Commerce and Industry of the Russian Federation, said that, over the past few years, the Russian pharmaceutical industry showed a steady growth and is a leader compared to the other industries. The year-over-year growth consistently remains above 10%. For example, in 2016, the pharmaceutical industry grew by almost 24%. For 2016, the output of medicinal products reached 285.87 billion rubles. 77% of vital and essential drugs are already produced in Russia.
There was a notable effect resulting from state support measures, such as subsidizing loans and providing loans from the Industrial Development Fund. In 2015-2017, the Fund approved 26 projects in the area of Medicine, Biotech and Pharmaceuticals.
All this makes the pharmaceutical industry attractive for investors. In the past 5 years, the industry attracted over 120 billion rubles of private foreign and Russian investments.
Foreign investments in the Russian pharmaceutical industry reached more than 1 billion euros. Many international companies, including Takeda, Astra Zeneca, Novo Nordisk, Teva, Novartis, Sanofi-Aventis, Abbott, Krka, Serdix, Gedeon Richter, and Stada, have built their plants in Russia.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024